18-62106862-C-A
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PP3_StrongPP5
The ENST00000640252.2(PIGN):c.1694G>T(p.Arg565Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000131 in 1,607,982 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R565C) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000640252.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PIGN | NM_176787.5 | c.1694G>T | p.Arg565Leu | missense_variant | 19/31 | ENST00000640252.2 | NP_789744.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PIGN | ENST00000640252.2 | c.1694G>T | p.Arg565Leu | missense_variant | 19/31 | 1 | NM_176787.5 | ENSP00000492233 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000855 AC: 13AN: 151966Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000125 AC: 3AN: 239518Hom.: 0 AF XY: 0.00000772 AC XY: 1AN XY: 129606
GnomAD4 exome AF: 0.00000549 AC: 8AN: 1456016Hom.: 0 Cov.: 31 AF XY: 0.00000553 AC XY: 4AN XY: 723616
GnomAD4 genome AF: 0.0000855 AC: 13AN: 151966Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74198
ClinVar
Submissions by phenotype
Multiple congenital anomalies-hypotonia-seizures syndrome 1 Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | Jun 20, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 15, 2024 | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 565 of the PIGN protein (p.Arg565Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features of PIGN-related conditions (PMID: 32220244, 35322241; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 391067). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PIGN protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 19, 2018 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
not provided Pathogenic:1Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 02, 2024 | Reported in a patient with features consistent with a PIGN-related disorder who had a second PIGN variant in trans (PMID: 32220244); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35322241, 38256219, Xiuwei_2021, 38456468, 32220244) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2023 | PIGN: PM2, PM3 - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 24, 2024 | The p.R565L variant (also known as c.1694G>T), located in coding exon 16 of the PIGN gene, results from a G to T substitution at nucleotide position 1694. The arginine at codon 565 is replaced by leucine, an amino acid with dissimilar properties. This variant has been confirmed in trans with a PIGN likely pathogenic/pathogenic variant in two individuals with clinical features of PIGN-related glycosylphosphatidylinositol deficiency (Ambry internal data; Brea-Fernández AJ et al. Eur J Hum Genet, 2022 Aug;30:938-945). Another alteration at the same codon, c.1694G>A (p.R565H), has been detected in an individual with clinical features consistent with PIGN-related glycosylphosphatidylinositol deficiency (Jiao X et al. Orphanet J Rare Dis, 2020 Mar;15:78). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at